Furthermore, co-blocking TIGIT and PD-1 not only relieves the inhibition of CD226 by PD-1 but also restores CD226 functionality, significantly enhancing the anti-tumor response of immune cells. The gene discussed is TIGIT; the disease is neoplasm.